Scholarlink

<p>Inhibitors of the sodium-glucose cotransporter-2 (SGLT2i) were initially created for managing diabetes mellitus but have suggested significant renoprotective advantages regardless of blood glucose levels. SGLT2-inhibitors have thus emerged as a crucial component in the therapeutic arsenal for managing patients with chronic kidney disease. This narrative review summarizes current mechanistic, preclinical and clinical evidence regarding SGLT2i in ADPKD. Nevertheless, certain patient groups were omitted from the key trials, such as individuals with extremely low estimated glomerular filtration rate (eGFR), those undergoing dialysis, kidney transplant patients, and individuals with autosomal dominant polycystic kidney disease (ADPKD), the most prevalent genetic kidney condition. Given the scarcity of effective treatment options in ADPKD, the application of SGLT2i in this group of patients would be significantly noteworthy. Nonetheless, the blend of inconclusive findings from preclinical models, along with the absence of clinical efficacy data and possible safety issues specific to the disease, presently prevents patients with ADPKD from benefiting from this promising therapeutic option. This creates an immediate demand for properly conducted clinical trials investigating SGLT2i in ADPKD. This narrative review encapsulates the existing understanding of SGLT2i in this particular patient group and highlights ongoing and future clinical trial initiatives across various geographic locations designed to provide SGLT2i to patients with ADPKD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Renal outcomes of SGLT2 inhibitors in ADPKD: a narrative review from mechanistic rationale to clinical trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Faiza Naeem,
  • Siew Chin Ong,
  • Muhammad Daoud Butt,
  • Amer Hayat Khan,
  • Azreen Syazril Adnan,
  • Shahzad Shaukat

摘要

Inhibitors of the sodium-glucose cotransporter-2 (SGLT2i) were initially created for managing diabetes mellitus but have suggested significant renoprotective advantages regardless of blood glucose levels. SGLT2-inhibitors have thus emerged as a crucial component in the therapeutic arsenal for managing patients with chronic kidney disease. This narrative review summarizes current mechanistic, preclinical and clinical evidence regarding SGLT2i in ADPKD. Nevertheless, certain patient groups were omitted from the key trials, such as individuals with extremely low estimated glomerular filtration rate (eGFR), those undergoing dialysis, kidney transplant patients, and individuals with autosomal dominant polycystic kidney disease (ADPKD), the most prevalent genetic kidney condition. Given the scarcity of effective treatment options in ADPKD, the application of SGLT2i in this group of patients would be significantly noteworthy. Nonetheless, the blend of inconclusive findings from preclinical models, along with the absence of clinical efficacy data and possible safety issues specific to the disease, presently prevents patients with ADPKD from benefiting from this promising therapeutic option. This creates an immediate demand for properly conducted clinical trials investigating SGLT2i in ADPKD. This narrative review encapsulates the existing understanding of SGLT2i in this particular patient group and highlights ongoing and future clinical trial initiatives across various geographic locations designed to provide SGLT2i to patients with ADPKD.